BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Di Fiore R, Marcatti M, Drago-Ferrante R, D'Anneo A, Giuliano M, Carlisi D, De Blasio A, Querques F, Pastore L, Tesoriere G, Vento R. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells. Bone 2014;60:198-212. [PMID: 24373920 DOI: 10.1016/j.bone.2013.12.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Curylova L, Ramos H, Saraiva L, Skoda J. Noncanonical roles of p53 in cancer stemness and their implications in sarcomas. Cancer Lett 2022;525:131-45. [PMID: 34742870 DOI: 10.1016/j.canlet.2021.10.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Synoradzki KJ, Bartnik E, Czarnecka AM, Fiedorowicz M, Firlej W, Brodziak A, Stasinska A, Rutkowski P, Grieb P. TP53 in Biology and Treatment of Osteosarcoma. Cancers (Basel) 2021;13:4284. [PMID: 34503094 DOI: 10.3390/cancers13174284] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Menéndez ST, Gallego B, Murillo D, Rodríguez A, Rodríguez R. Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas. J Clin Med 2021;10:2621. [PMID: 34198693 DOI: 10.3390/jcm10122621] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
4 Emanuele S, Giuliano M. Dual Function Molecules and Processes in Cell Fate Decision: A Preface to the Special Issue. Int J Mol Sci 2020;21:E9601. [PMID: 33339424 DOI: 10.3390/ijms21249601] [Reference Citation Analysis]
5 Koifman G, Aloni-Grinstein R, Rotter V. p53 balances between tissue hierarchy and anarchy. J Mol Cell Biol 2019;11:553-63. [PMID: 30925590 DOI: 10.1093/jmcb/mjz022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
6 Schmidt K, Carroll JS, Yee E, Thomas DD, Wert-Lamas L, Neier SC, Sheynkman G, Ritz J, Novina CD. The lncRNA SLNCR Recruits the Androgen Receptor to EGR1-Bound Genes in Melanoma and Inhibits Expression of Tumor Suppressor p21. Cell Rep 2019;27:2493-2507.e4. [PMID: 31116991 DOI: 10.1016/j.celrep.2019.04.101] [Cited by in Crossref: 32] [Cited by in F6Publishing: 42] [Article Influence: 10.7] [Reference Citation Analysis]
7 Zhang C, Yang Z, Dong DL, Jang TS, Knowles JC, Kim HW, Jin GZ, Xuan Y. 3D culture technologies of cancer stem cells: promising ex vivo tumor models. J Tissue Eng 2020;11:2041731420933407. [PMID: 32637062 DOI: 10.1177/2041731420933407] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
8 Cheng M, Huang W, Cai W, Fang M, Chen Y, Wang C, Yan W. Growth hormone receptor promotes osteosarcoma cell growth and metastases. FEBS Open Bio 2020;10:127-34. [PMID: 31725956 DOI: 10.1002/2211-5463.12761] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Pitolli C, Wang Y, Mancini M, Shi Y, Melino G, Amelio I. Do Mutations Turn p53 into an Oncogene? Int J Mol Sci. 2019;20:6241. [PMID: 31835684 DOI: 10.3390/ijms20246241] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
10 Long X, Lin X. P65‐mediated miR‐590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild‐type p53‐induced phosphatase 1. J Cell Biochem 2019;120:5652-65. [DOI: 10.1002/jcb.27849] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
11 Drago-Ferrante R, Pentimalli F, Carlisi D, De Blasio A, Saliba C, Baldacchino S, Degaetano J, Debono J, Caruana-Dingli G, Grech G, Scerri C, Tesoriere G, Giordano A, Vento R, Di Fiore R. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation. Oncotarget 2017;8:28939-58. [PMID: 28423652 DOI: 10.18632/oncotarget.15960] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
12 Hosain SB, Khiste SK, Uddin MB, Vorubindi V, Ingram C, Zhang S, Hill RA, Gu X, Liu YY. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells. Oncotarget 2016;7:60575-92. [PMID: 27517620 DOI: 10.18632/oncotarget.11169] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
13 Solomon H, Dinowitz N, Pateras IS, Cooks T, Shetzer Y, Molchadsky A, Charni M, Rabani S, Koifman G, Tarcic O, Porat Z, Kogan-Sakin I, Goldfinger N, Oren M, Harris CC, Gorgoulis VG, Rotter V. Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers. Oncogene. 2018;37:1669-1684. [PMID: 29343849 DOI: 10.1038/s41388-017-0060-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 10.4] [Reference Citation Analysis]
14 Ferreira de Oliveira JMP, Pacheco AR, Coutinho L, Oliveira H, Pinho S, Almeida L, Fernandes E, Santos C. Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models. Arch Toxicol 2018;92:1205-14. [PMID: 29270805 DOI: 10.1007/s00204-017-2146-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
15 He J, Xiong L, Li Q, Lin L, Miao X, Yan S, Hong Z, Yang L, Wen Y, Deng X. 3D modeling of cancer stem cell niche. Oncotarget 2018;9:1326-45. [PMID: 29416698 DOI: 10.18632/oncotarget.19847] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
16 Zhang Y, Hu Y, Wang J, Yao H, Wang H, Liang L, Li C, Shi H, Chen Y, Fang J, Xu J. Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp. Oncogene 2017;36:5473-83. [DOI: 10.1038/onc.2017.152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
17 Molchadsky A, Rotter V. p53 and its mutants on the slippery road from stemness to carcinogenesis. Carcinogenesis 2017;38:347-58. [PMID: 28334334 DOI: 10.1093/carcin/bgw092] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
18 Shetzer Y, Molchadsky A, Rotter V. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. Cold Spring Harb Perspect Med 2016;6:a026203. [PMID: 27235476 DOI: 10.1101/cshperspect.a026203] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
19 Chen Z, Guo J, Zhang K, Guo Y. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data. Dis Markers 2016;2016:4639575. [PMID: 27239089 DOI: 10.1155/2016/4639575] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
20 Carlisi D, Buttitta G, Di Fiore R, Scerri C, Drago-Ferrante R, Vento R, Tesoriere G. Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis. Cell Death Dis 2016;7:e2194. [PMID: 27077810 DOI: 10.1038/cddis.2016.94] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
21 Lu B, Huang X, Mo J, Zhao W. Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting. Front Pharmacol 2016;7:84. [PMID: 27148051 DOI: 10.3389/fphar.2016.00084] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 6.3] [Reference Citation Analysis]
22 Swanson MS, Kokot N, Sinha UK. The Role of HPV in Head and Neck Cancer Stem Cell Formation and Tumorigenesis. Cancers (Basel) 2016;8:E24. [PMID: 26907349 DOI: 10.3390/cancers8020024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
23 Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, Carlisi D, De Blasio A, Tesoriere G, Giordano A, Vento R. Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells. J Cell Physiol 2016;231:1832-41. [PMID: 26679758 DOI: 10.1002/jcp.25291] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
24 Wang J, Xie H, Gao F, Zhao T, Yang H, Kang B. Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway. Tumour Biol 2016;37:4203-12. [PMID: 26490992 DOI: 10.1007/s13277-015-4029-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
25 Simple M, Suresh A, Das D, Kuriakose MA. Cancer stem cells and field cancerization of Oral squamous cell carcinoma. Oral Oncology 2015;51:643-51. [DOI: 10.1016/j.oraloncology.2015.04.006] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
26 Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, D’Anneo A, Carlisi D, De Blasio A, Giuliano M, Tesoriere G. MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 2014;45:2013-2023. [PMID: 25174983 DOI: 10.3892/ijo.2014.2618] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]